Clinical Trial Update: Olaptesed With Pembrolizumab and Nanoliposomal Irinotecan or Gemcitabine/Nab-Paclitaxel in MSS Pancreatic Cancer [Phase 2]

View source ↗

Summary

This Phase 2 clinical trial update from TME Pharma explores olaptesed pegol in combination with pembrolizumab and either nanoliposomal irinotecan or gemcitabine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• Nanoliposomal irinotecan (irinotecan liposomal)
• Olaptesed pegol (olaptesed pegol)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: TME Pharma AG | Conditions: Metastatic Pancreatic Cancer | Phase 2 | Status: NOT_YET_RECRUITING